Your browser doesn't support javascript.
loading
Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study.
Corcoran, John P; Psallidas, Ioannis; Gerry, Stephen; Piccolo, Francesco; Koegelenberg, Coenraad F; Saba, Tarek; Daneshvar, Cyrus; Fairbairn, Ian; Heinink, Richard; West, Alex; Stanton, Andrew E; Holme, Jayne; Kastelik, Jack A; Steer, Henry; Downer, Nicola J; Haris, Mohammed; Baker, Emma H; Everett, Caroline F; Pepperell, Justin; Bewick, Thomas; Yarmus, Lonny; Maldonado, Fabien; Khan, Burhan; Hart-Thomas, Alan; Hands, Georgina; Warwick, Geoffrey; De Fonseka, Duneesha; Hassan, Maged; Munavvar, Mohammed; Guhan, Anur; Shahidi, Mitra; Pogson, Zara; Dowson, Lee; Popowicz, Natalia D; Saba, Judith; Ward, Neil R; Hallifax, Rob J; Dobson, Melissa; Shaw, Rachel; Hedley, Emma L; Sabia, Assunta; Robinson, Barbara; Collins, Gary S; Davies, Helen E; Yu, Ly-Mee; Miller, Robert F; Maskell, Nick A; Rahman, Najib M.
Afiliação
  • Corcoran JP; Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Psallidas I; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Gerry S; Joint first authors, with equal contribution to study recruitment and manuscript writing.
  • Piccolo F; Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Koegelenberg CF; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Saba T; Joint first authors, with equal contribution to study recruitment and manuscript writing.
  • Daneshvar C; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Fairbairn I; Dept of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
  • Heinink R; Division of Pulmonology, Dept of Medicine, Stellenbosch University, Cape Town, South Africa.
  • West A; Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK.
  • Stanton AE; University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Holme J; Victoria Hospital, NHS Fife, Kirkcaldy, UK.
  • Kastelik JA; Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
  • Steer H; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Downer NJ; Great Western Hospitals NHS Foundation Trust, Swindon, UK.
  • Haris M; University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
  • Baker EH; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
  • Everett CF; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
  • Pepperell J; Sherwood Forest Hospitals NHS Foundation Trust, Mansfield, UK.
  • Bewick T; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
  • Yarmus L; Institute of Infection and Immunity, St George's, University of London, London, UK.
  • Maldonado F; York Teaching Hospitals NHS Foundation Trust, York, UK.
  • Khan B; Taunton and Somerset NHS Foundation Trust, Taunton, UK.
  • Hart-Thomas A; Derby Teaching Hospitals NHS Foundation Trust, Derby, UK.
  • Hands G; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Warwick G; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • De Fonseka D; Dartford and Gravesham NHS Trust, Dartford, UK.
  • Hassan M; Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK.
  • Munavvar M; Northern Devon Healthcare NHS Trust, Barnstaple, UK.
  • Guhan A; King's College Hospital NHS Foundation Trust, London, UK.
  • Shahidi M; Academic Respiratory Unit, University of Bristol, Bristol, UK.
  • Pogson Z; Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Dowson L; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Popowicz ND; Chest Diseases Dept, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Saba J; Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
  • Ward NR; University Hospital Ayr, NHS Ayrshire and Arran, Ayr, UK.
  • Hallifax RJ; Buckinghamshire Healthcare NHS Trust, Amersham, UK.
  • Dobson M; United Lincolnshire Hospitals NHS Trust, Lincoln, UK.
  • Shaw R; Royal Wolverhampton Hospital NHS Trust, Wolverhampton, UK.
  • Hedley EL; Dept of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
  • Sabia A; Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK.
  • Robinson B; University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Collins GS; Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Davies HE; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Yu LM; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Miller RF; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Maskell NA; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
  • Rahman NM; Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
Eur Respir J ; 56(5)2020 11.
Article em En | MEDLINE | ID: mdl-32675200
BACKGROUND: Over 30% of adult patients with pleural infection either die and/or require surgery. There is no robust means of predicting at baseline presentation which patients will suffer a poor clinical outcome. A validated risk prediction score would allow early identification of high-risk patients, potentially directing more aggressive treatment thereafter. OBJECTIVES: To prospectively assess a previously described risk score (the RAPID (Renal (urea), Age, fluid Purulence, Infection source, Dietary (albumin)) score) in adults with pleural infection. METHODS: Prospective observational cohort study that recruited patients undergoing treatment for pleural infection. RAPID score and risk category were calculated at baseline presentation. The primary outcome was mortality at 3 months; secondary outcomes were mortality at 12 months, length of hospital stay, need for thoracic surgery, failure of medical treatment and lung function at 3 months. RESULTS: Mortality data were available in 542 out of 546 patients recruited (99.3%). Overall mortality was 10% at 3 months (54 out of 542) and 19% at 12 months (102 out of 542). The RAPID risk category predicted mortality at 3 months. Low-risk mortality (RAPID score 0-2): five out of 222 (2.3%, 95% CI 0.9 to 5.7%); medium-risk mortality (RAPID score 3-4): 21 out of 228 (9.2%, 95% CI 6.0 to 13.7%); and high-risk mortality (RAPID score 5-7): 27 out of 92 (29.3%, 95% CI 21.0 to 39.2%). C-statistics for the scores at 3 months and 12 months were 0.78 (95% CI 0.71-0.83) and 0.77 (95% CI 0.72-0.82), respectively. CONCLUSIONS: The RAPID score stratifies adults with pleural infection according to increasing risk of mortality and should inform future research directed at improving outcomes in this patient population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Pleurais Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Pleurais Idioma: En Ano de publicação: 2020 Tipo de documento: Article